NEW YORK — January 12, 2026 — Mostik AI, a full-stack, AI native drug discovery and development company, today announced it has entered into a strategic agreement with Schrödinger, Inc. The agreement grants Mostik AI significant access to Schrödinger’s industry-leading physics-based computational platform, positioning Mostik AI at the forefront of AI-driven molecular discovery. Mostik AI is building a first-in-class physics based atomic “world model” that aspires to be an AI-enabled oracle for the discovery of novel binders to target proteins involved in pathological processes. Mostik AI’s proprietary algorithms are designed to find binders of all molecular classes, including small molecules, nanobodies, and siRNA targets.
This agreement includes deep access to Schrödinger’s computational molecular discovery platform combined with expert support aimed at optimizing the impact of the platform. This bespoke level of technology access is designed to ensure Mostik AI’s algorithms are fully harmonized with Schrödinger’s predictive power.
“Our mission at Mostik AI is to solve the most complex challenges in drug discovery and development by merging the best of AI with the most rigorous physics,” said Sasha Malysheva, CEO of Mostik AI. “By securing this level of unique access and specialized support from Schrödinger, we intend to significantly shorten our discovery timelines. This isn’t just an addition to our toolkit; it is a foundational pillar of our discovery engine that we believe gives us a distinct competitive advantage.”
The strategic agreement is designed to enable: (1) unique platform access that will allow Mostik AI to leverage Schrödinger’s platform at an ultra-large scale; (2) direct, priority access to Schrödinger’s talented scientific and technical teams to optimize Mostik AI’s internal computational workflows; and (3) integration of Schrödinger’s physics-based modeling with Mostik AI’s machine learning models to improve predictive accuracy and speed.
“The next frontier in drug discovery is the seamless convergence of physics and AI, and we are very impressed by the sophisticated approach Mostik AI is taking,” said Pat Lorton, Chief Technology Officer and Chief Operating Officer, Software at Schrödinger. “Because of the scale and ambition of their vision, we have committed to a deeper level of support and platform access to ensure Mostik AI is enabled by the full potential of our technology across modalities.”
This multi-year agreement represents a dedication to excellence in digital discovery, ensuring that Mostik AI is equipped with the most advanced computational tools available to transform drug discovery. Financial terms of the agreement are not disclosed.
About Mostik AI
Co-founded by Sasha Malysheva, Reid Hoffman, and Ujjwal Singh, Mostik AI builds and uses neuro-symbolic, science-based foundational models to discover and bring transformative medicines to market. Mostik AI is headquartered in New York City, NY.